Bayer’s NUBEQA combo shows 71% drop in risk of progression or death in prostate cancer trial

Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm

Zeus Hygia launches Metaberine in Europe and US markets

Next-generation berberine formulation developed with BioSOLVE Technology targets metabolic health, blood sugar balance, and weight management

NunaBio secures £6.5 million to scale DNA manufacturing platform

Funding to accelerate development of integrated DNA platform supporting vaccines, gene therapies and advanced biologics

SN Bioscience doses first patient in global trial of experimental drug for aggressive lung cancer

The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients

OrganaBio expands cell therapy manufacturing footprint with acquisition of Excellos Assets

The deal also establishes a new subsidiary, Excellos Labs, which will oversee continued operations in San Diego

ParexelAI launched to accelerate clinical development and improve trial efficiency

The platform combines internally developed technologies, strategic partnerships, and external AI capabilities

Merck reports breakthrough Phase 3 win for sac-TMT in endometrial cancer

Africa CDC warns of regional Ebola spread risk as DRC and Uganda confirm outbreaks

Africa CDC activates continental coordination measures; consultations underway on possible Public Health Emergency declaration

Caplin Steriles receives USFDA approval for generic foscarnet sodium injection

Antiviral injection addressing CMV and HSV infections had US market sales of nearly $15 million in the last 12 months

Strides Pharma reports Rs. 2,489.7 crore revenue during FY26, 2% YoY growth

Ex-US revenue rose sharply by 21% YoY to Rs. 2, 240.4 crore ($254 million); Operational PAT grew 50.3% YoY to Rs. 518.1 crore